<?xml version='1.0' encoding='utf-8'?>
<document id="15194707"><sentence text="Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil."><entity charOffset="0-11" id="DDI-PubMed.15194707.s1.e0" text="Gemfibrozil" /><entity charOffset="20-31" id="DDI-PubMed.15194707.s1.e1" text="glucuronide" /><entity charOffset="167-179" id="DDI-PubMed.15194707.s1.e2" text="cerivastatin" /><entity charOffset="264-276" id="DDI-PubMed.15194707.s1.e3" text="cerivastatin" /><entity charOffset="281-292" id="DDI-PubMed.15194707.s1.e4" text="gemfibrozil" /><pair ddi="false" e1="DDI-PubMed.15194707.s1.e0" e2="DDI-PubMed.15194707.s1.e0" /><pair ddi="false" e1="DDI-PubMed.15194707.s1.e0" e2="DDI-PubMed.15194707.s1.e1" /><pair ddi="false" e1="DDI-PubMed.15194707.s1.e0" e2="DDI-PubMed.15194707.s1.e2" /><pair ddi="false" e1="DDI-PubMed.15194707.s1.e0" e2="DDI-PubMed.15194707.s1.e3" /><pair ddi="false" e1="DDI-PubMed.15194707.s1.e0" e2="DDI-PubMed.15194707.s1.e4" /><pair ddi="false" e1="DDI-PubMed.15194707.s1.e1" e2="DDI-PubMed.15194707.s1.e1" /><pair ddi="false" e1="DDI-PubMed.15194707.s1.e1" e2="DDI-PubMed.15194707.s1.e2" /><pair ddi="false" e1="DDI-PubMed.15194707.s1.e1" e2="DDI-PubMed.15194707.s1.e3" /><pair ddi="false" e1="DDI-PubMed.15194707.s1.e1" e2="DDI-PubMed.15194707.s1.e4" /><pair ddi="false" e1="DDI-PubMed.15194707.s1.e2" e2="DDI-PubMed.15194707.s1.e2" /><pair ddi="false" e1="DDI-PubMed.15194707.s1.e2" e2="DDI-PubMed.15194707.s1.e3" /><pair ddi="false" e1="DDI-PubMed.15194707.s1.e2" e2="DDI-PubMed.15194707.s1.e4" /><pair ddi="false" e1="DDI-PubMed.15194707.s1.e3" e2="DDI-PubMed.15194707.s1.e3" /><pair ddi="false" e1="DDI-PubMed.15194707.s1.e3" e2="DDI-PubMed.15194707.s1.e4" /></sentence><sentence text="A serious pharmacokinetic interaction between cerivastatin (CER) and gemfibrozil (GEM) has been reported"><entity charOffset="46-58" id="DDI-PubMed.15194707.s2.e0" text="cerivastatin" /><entity charOffset="60-63" id="DDI-PubMed.15194707.s2.e1" text="CER" /><entity charOffset="69-80" id="DDI-PubMed.15194707.s2.e2" text="gemfibrozil" /><entity charOffset="82-85" id="DDI-PubMed.15194707.s2.e3" text="GEM" /><pair ddi="false" e1="DDI-PubMed.15194707.s2.e0" e2="DDI-PubMed.15194707.s2.e0" /><pair ddi="false" e1="DDI-PubMed.15194707.s2.e0" e2="DDI-PubMed.15194707.s2.e1" /><pair ddi="false" e1="DDI-PubMed.15194707.s2.e0" e2="DDI-PubMed.15194707.s2.e2" /><pair ddi="false" e1="DDI-PubMed.15194707.s2.e0" e2="DDI-PubMed.15194707.s2.e3" /><pair ddi="false" e1="DDI-PubMed.15194707.s2.e1" e2="DDI-PubMed.15194707.s2.e1" /><pair ddi="false" e1="DDI-PubMed.15194707.s2.e1" e2="DDI-PubMed.15194707.s2.e2" /><pair ddi="false" e1="DDI-PubMed.15194707.s2.e1" e2="DDI-PubMed.15194707.s2.e3" /><pair ddi="false" e1="DDI-PubMed.15194707.s2.e2" e2="DDI-PubMed.15194707.s2.e2" /><pair ddi="false" e1="DDI-PubMed.15194707.s2.e2" e2="DDI-PubMed.15194707.s2.e3" /></sentence><sentence text=" In the present study, we examined the inhibitory effects of GEM and its metabolites, M3 and gemfibrozil 1-O-beta-glucuronide (GEM-1-O-glu), on the uptake of CER by human organic anion transporting polypeptide 2 (OATP2)-expressing cells and its metabolism in cytochrome P450 expression systems"><entity charOffset="93-125" id="DDI-PubMed.15194707.s3.e0" text="gemfibrozil 1-O-beta-glucuronide" /><entity charOffset="127-138" id="DDI-PubMed.15194707.s3.e1" text="GEM-1-O-glu" /><entity charOffset="158-168" id="DDI-PubMed.15194707.s3.e2" text="CER" /><entity charOffset="61-71" id="DDI-PubMed.15194707.s3.e3" text="GEM" /><pair ddi="false" e1="DDI-PubMed.15194707.s3.e3" e2="DDI-PubMed.15194707.s3.e3" /><pair ddi="false" e1="DDI-PubMed.15194707.s3.e3" e2="DDI-PubMed.15194707.s3.e0" /><pair ddi="false" e1="DDI-PubMed.15194707.s3.e3" e2="DDI-PubMed.15194707.s3.e1" /><pair ddi="false" e1="DDI-PubMed.15194707.s3.e3" e2="DDI-PubMed.15194707.s3.e2" /><pair ddi="false" e1="DDI-PubMed.15194707.s3.e0" e2="DDI-PubMed.15194707.s3.e0" /><pair ddi="false" e1="DDI-PubMed.15194707.s3.e0" e2="DDI-PubMed.15194707.s3.e1" /><pair ddi="false" e1="DDI-PubMed.15194707.s3.e0" e2="DDI-PubMed.15194707.s3.e2" /><pair ddi="false" e1="DDI-PubMed.15194707.s3.e1" e2="DDI-PubMed.15194707.s3.e1" /><pair ddi="false" e1="DDI-PubMed.15194707.s3.e1" e2="DDI-PubMed.15194707.s3.e2" /></sentence><sentence text=" Uptake studies showed that GEM and GEM-1-O-glu significantly inhibited the OATP2-mediated uptake of CER with IC(50) values of 72 and 24 microM, respectively"><entity charOffset="101-103" id="DDI-PubMed.15194707.s4.e0" text="CER" /><entity charOffset="28-30" id="DDI-PubMed.15194707.s4.e1" text="GEM" /><entity charOffset="36-38" id="DDI-PubMed.15194707.s4.e2" text="GEM" /><pair ddi="false" e1="DDI-PubMed.15194707.s4.e1" e2="DDI-PubMed.15194707.s4.e1" /><pair ddi="false" e1="DDI-PubMed.15194707.s4.e1" e2="DDI-PubMed.15194707.s4.e2" /><pair ddi="false" e1="DDI-PubMed.15194707.s4.e1" e2="DDI-PubMed.15194707.s4.e0" /><pair ddi="false" e1="DDI-PubMed.15194707.s4.e2" e2="DDI-PubMed.15194707.s4.e2" /><pair ddi="false" e1="DDI-PubMed.15194707.s4.e2" e2="DDI-PubMed.15194707.s4.e0" /></sentence><sentence text=" They also inhibited the CYP2C8-mediated metabolism of CER with IC(50) values of 28 and 4 microM, respectively, whereas M3 had no effects"><entity charOffset="55-57" id="DDI-PubMed.15194707.s5.e0" text="CER" /></sentence><sentence text=" GEM and GEM-1-O-glu minimally inhibited the CYP3A4-mediated metabolism of CER"><entity charOffset="75-77" id="DDI-PubMed.15194707.s6.e0" text="CER" /><entity charOffset="1-3" id="DDI-PubMed.15194707.s6.e1" text="GEM" /><entity charOffset="9-11" id="DDI-PubMed.15194707.s6.e2" text="GEM" /><pair ddi="false" e1="DDI-PubMed.15194707.s6.e1" e2="DDI-PubMed.15194707.s6.e1" /><pair ddi="false" e1="DDI-PubMed.15194707.s6.e1" e2="DDI-PubMed.15194707.s6.e2" /><pair ddi="false" e1="DDI-PubMed.15194707.s6.e1" e2="DDI-PubMed.15194707.s6.e0" /><pair ddi="false" e1="DDI-PubMed.15194707.s6.e2" e2="DDI-PubMed.15194707.s6.e2" /><pair ddi="false" e1="DDI-PubMed.15194707.s6.e2" e2="DDI-PubMed.15194707.s6.e0" /></sentence><sentence text=" The IC(50) values of GEM and GEM-1-O-glu for the uptake and the metabolism of CER obtained in the present study were lower than their total, and not unbound, plasma concentrations"><entity charOffset="30-41" id="DDI-PubMed.15194707.s7.e0" text="GEM-1-O-glu" /><entity charOffset="79-89" id="DDI-PubMed.15194707.s7.e1" text="CER" /><entity charOffset="22-32" id="DDI-PubMed.15194707.s7.e2" text="GEM" /><pair ddi="false" e1="DDI-PubMed.15194707.s7.e2" e2="DDI-PubMed.15194707.s7.e2" /><pair ddi="false" e1="DDI-PubMed.15194707.s7.e2" e2="DDI-PubMed.15194707.s7.e0" /><pair ddi="false" e1="DDI-PubMed.15194707.s7.e2" e2="DDI-PubMed.15194707.s7.e1" /><pair ddi="false" e1="DDI-PubMed.15194707.s7.e0" e2="DDI-PubMed.15194707.s7.e0" /><pair ddi="false" e1="DDI-PubMed.15194707.s7.e0" e2="DDI-PubMed.15194707.s7.e1" /></sentence><sentence text=" However, considering the possibly concentrated high unbound concentrations of GEM-1-O-glu in the liver and its relatively larger plasma unbound fraction compared with GEM itself, the glucuronide inhibition of the CYP2C8-mediated metabolism of CER appears to be the main mechanism for the clinically relevant drug-drug interaction"><entity charOffset="79-90" id="DDI-PubMed.15194707.s8.e0" text="GEM-1-O-glu" /><entity charOffset="184-195" id="DDI-PubMed.15194707.s8.e1" text="glucuronide" /><entity charOffset="244-254" id="DDI-PubMed.15194707.s8.e2" text="CER" /><entity charOffset="168-178" id="DDI-PubMed.15194707.s8.e3" text="GEM" /><pair ddi="false" e1="DDI-PubMed.15194707.s8.e0" e2="DDI-PubMed.15194707.s8.e0" /><pair ddi="false" e1="DDI-PubMed.15194707.s8.e0" e2="DDI-PubMed.15194707.s8.e3" /><pair ddi="false" e1="DDI-PubMed.15194707.s8.e0" e2="DDI-PubMed.15194707.s8.e1" /><pair ddi="false" e1="DDI-PubMed.15194707.s8.e0" e2="DDI-PubMed.15194707.s8.e2" /><pair ddi="false" e1="DDI-PubMed.15194707.s8.e3" e2="DDI-PubMed.15194707.s8.e3" /><pair ddi="false" e1="DDI-PubMed.15194707.s8.e3" e2="DDI-PubMed.15194707.s8.e1" /><pair ddi="false" e1="DDI-PubMed.15194707.s8.e3" e2="DDI-PubMed.15194707.s8.e2" /><pair ddi="false" e1="DDI-PubMed.15194707.s8.e1" e2="DDI-PubMed.15194707.s8.e1" /><pair ddi="false" e1="DDI-PubMed.15194707.s8.e1" e2="DDI-PubMed.15194707.s8.e2" /></sentence><sentence text=" Previously reported clinical drug interaction studies showing that coadministration of GEM with pravastatin or pitavastatin, both of which are known to be cleared from the plasma by the uptake transporters in the liver, only minimally (less than 2-fold) increased the area under the plasma concentration-time curve of these statins, also supported our present conclusion"><entity charOffset="97-108" id="DDI-PubMed.15194707.s9.e0" text="pravastatin" /><entity charOffset="112-124" id="DDI-PubMed.15194707.s9.e1" text="pitavastatin" /><entity charOffset="88-99" id="DDI-PubMed.15194707.s9.e2" text="GEM" /><pair ddi="false" e1="DDI-PubMed.15194707.s9.e2" e2="DDI-PubMed.15194707.s9.e2" /><pair ddi="false" e1="DDI-PubMed.15194707.s9.e2" e2="DDI-PubMed.15194707.s9.e0" /><pair ddi="false" e1="DDI-PubMed.15194707.s9.e2" e2="DDI-PubMed.15194707.s9.e1" /><pair ddi="false" e1="DDI-PubMed.15194707.s9.e0" e2="DDI-PubMed.15194707.s9.e0" /><pair ddi="false" e1="DDI-PubMed.15194707.s9.e0" e2="DDI-PubMed.15194707.s9.e1" /></sentence><sentence text="" /></document>